SELECT trial: difference between revisions
Diff·revision 7 → 8·21:29, 2 Nov 2024
Difference between revision 7 and revision 8 of SELECT trial. 10 lines changed; the page grew by 720 bytes.
| Revision 7 — 07:34, 15 Oct 2024 KPV_Kester (talk) split overlong sentence 2,782 bytes +454 | Revision 8 — 21:29, 2 Nov 2024 CategoryBot (talk) bot: sort category members 3,502 bytes +720 | ||
|---|---|---|---|
| 20 | Mean weight reduction on active treatment was about 9.4%, less than the 14.9% seen in [[STEP trial programme|STEP 1]] — a reminder that trial populations differ and that an effect size does not transfer between them.{{r|wilding2021}} | 20 | Mean weight reduction on active treatment was about 9.4%, less than the 14.9% seen in [[STEP trial programme|STEP 1]] — a reminder that trial populations differ and that an effect size does not transfer between them.{{r|wilding2021}} |
| 21 | 21 | ||
| + | 22 | == Results and their interpretation == | |
| + | 23 | | Endpoint | Semaglutide | Placebo | Effect | | |
| + | 24 | |---|---|---|---| | |
| + | 25 | | Primary composite | 6.5% | 8.0% | HR 0.80 (0.72–0.90) | | |
| + | 26 | | Cardiovascular death | 2.5% | 3.0% | Directionally consistent | | |
| + | 27 | | Non-fatal myocardial infarction | 2.7% | 3.7% | Directionally consistent | | |
| + | 28 | | Discontinuation for adverse events | 16.6% | 8.2% | Mostly gastrointestinal | | |
| + | 29 | ||
| + | 30 | Separation of the event curves began early, within the first months, before the majority of weight loss had occurred. Whether the benefit is mediated by weight reduction, by direct vascular effects, by improvements in blood pressure and inflammatory markers, or by some combination is not established by the trial.{{r|lincoff2023}} | |
| + | 31 | ||
| 22 | == References == | 32 | == References == |
| 23 | {{reflist}} | 33 | {{reflist}} |